Introduction: Urinary tract infections (UTIs) affect more than 150 million individuals annually. A strong correlation exists between bladder epithelia invasion by uropathogenic bacteria and patients with recurrent UTIs. Intracellular bacteria often recolonise epithelial cells post-antibiotic treatment. We investigated whether N-acetylcysteine (NAC) could prevent uropathogenic E. coli and E. faecalis bladder cell invasion, in addition to its effect on uropathogens when used alone or in combination with ciprofloxacin. Methods: An invasion assay was performed in which bacteria were added to bladder epithelial cells (BECs) in presence of NAC and invasion was allowed to occur. Cells were washed with gentamicin, lysed, and plated for enumeration of the intracellular bacterial load. Cytotoxicity was evaluated by exposing BECs to various concentrations of NAC and quantifying the metabolic activity using resazurin at different exposure times. The effect of NAC on the preformed biofilms was also investigated by treating 48 h biofilms for 24 h and enumerating colony counts. Bacteria were stained with propidium iodide (PI) to measure membrane damage. Results: NAC completely inhibited BEC invasion by multiple E. coli and E. faecalis clinical strains in a dose-dependent manner (p < 0.01). This was also evident when bacterial invasion was visualised using GFP-tagged E. coli. NAC displayed no cytotoxicity against BECs despite its intrinsic acidity (pH ~2.6), with >90% cellular viability 48 h post-exposure. NAC also prevented biofilm formation by E. coli and E. faecalis and significantly reduced bacterial loads in 48 h biofilms when combined with ciprofloxacin. NAC visibly damaged E. coli and E. faecalis bacterial membranes, with a threefold increase in propidium iodide-stained cells following treatment (p < 0.05). Conclusions: NAC is a non-toxic, antibiofilm agent in vitro and can prevent cell invasion and IBC formation by uropathogens, thus providing a potentially novel and efficacious treatment for UTIs. When combined with an antibiotic, it may disrupt bacterial biofilms and eliminate residual bacteria.
1 August 2021 in International Journal of Antimicrobial Agents
Uropathogenic Pseudomonas aeruginosa is a significant contributor to catheter-associated urinary tract infections (CA-UTIs), distinguished by its unique biofilm-forming properties compared to other strains. Despite its clinical significance, optimized strategies for biofilm eradication in the bladder and on catheters remain limited. Thus, the aim of this study was to highlight the potent antibacterial and biofilm-inhibitory effects of N-acetyl cysteine (NAC) against uropathogenic P. aeruginosa. Additionally, we sought to investigate its effect against catheter obstruction caused by P. aeruginosa in a patient, and whether this phenomenon can be replicated in vitro to underscore the urgency of addressing this critical challenge. We demonstrated that uropathogenic P. aeruginosa form thick, mucoid biofilms in vitro that can heavily occlude catheters, with bacterial titres of between 108 and 1011 CFU/cm, thus impairing catheter functionality. Furthermore, treatment with NAC significantly reduced viable bacteria by > 4log10 (p < 0.01), and inhibited biofilm formation and associated obstruction till experiment endpoint (96h). NAC also displayed significant bactericidal activity (p < 0.001) against P. aeruginosa and significantly impeded bacterial attachment and aggregation through modulation of colloidal forces and change in the structure of the bacterial cell surface, thus impairing the bacterium's ability to initiate biofilm development. Mechanistically, NAC alters the bacterial surface structure, disrupting biofilm-associated virulence. Hence our study found that NAC treatment physically disrupts uropathogenic P. aeruginosa biofilms and significantly alters its virulence. Our novel findings highlight the dual bactericidal and anti-biofilm properties of NAC in vitro, offering valuable insights into its potential application for preventing P. aeruginosa biofilm formation and catheter blockage in CA-UTI management.
Background: The presence of intracellular bacterial communities (IBCs) in the urothelium has been well documented in adults with chronic urinary tract infections (UTIs), but its long-term persistence going undetected in a severely symptomatic adolescent has not been reported. Case Summary: We present the case of a 14-year-old girl suffering from debilitating chronic UTI symptoms and associated urinary incontinence for many years. Multiple antibiotic courses provided only temporary relief, with positive Escherichia coli cultures recurring promptly after each treatment cycle. A recently conducted cystoscopy (after >6 years of persistent symptoms) revealed widespread squamous metaplasia of the bladder wall, and enhanced urinary analysis identified extensive intracellular bacterial ( E. coli ) communities in exfoliated urothelial cells. These intracellular bacterial communities persisted even when the urine became transiently culture negative on antibiotic treatment. Evidence from confocal microscopy demonstrated extensive intracellular E. coli , which may serve as a bacterial reservoir that seeds urinary reinfection when antibiotics are ceased. Persistent intracellular bacteria were not detected by routine urine microscopy and culture. Analysis of urinary cytokines suggested chronic inflammation of the bladder wall, driven by persistent bacterial infection, as the potential cause for the unrelenting symptoms. Conclusion: This is the first report demonstrating long-term undetected IBC in a severely symptomatic child with chronic UTI. It underscores the need to learn more about intracellular bacteria and urinary tract biofilms that are protected from antibiotics and host immunity. IBC reservoirs seem to drive bladder wall inflammation, exacerbating clinical symptoms and increasing the risk of long-term adverse sequelae.